A Randomized, Open-label, Parallel-group, Multi-center Phase 2a Study to Evaluate the Efficacy and Safety of CU06-1004 for 12 Weeks in Patients With Diabetic Macular Edema (DME)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CU 06 (Primary)
Indications Diabetic macular oedema; Wet age-related macular degeneration; Wet macular degeneration
Focus Therapeutic Use
Sponsors CURACLE

01 May 2024 Status changed from active, no longer recruiting to completed.
18 Dec 2023 According to CURACLE media release, this study is nearing the end of its phase 2a in the U.S.top executives and researchers from both companies will gather to discuss follow-up clinical development strategies and detailed operational plans for each scenario of the U.S. phase 2a clinical trial results.
13 Dec 2023 According to CURACLE media release, topline trial results expected in Q1 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com